The odds are stacked against Alder BioPharmaceuticals, a company of about 200 based in Bothell, Washington. This February, Alder filed an application for U.S. approval of its drug eptinezumab, which blocks a protein called CGRP that's also the target of the therapies from its three would-be pharma rivals.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,